



Gavi Alliance Board Meeting
 14-15 June 2017
 Intercontinental Hotel, Geneva, Switzerland

Quorum: 14

Declarations of Interest

Declarations

Section 5.2 of the Conflict of Interest Policy states, “Annually, each member of the Board (including alternate Board members and Committee delegates)...shall complete and submit a conflict of interest form to be distributed by the Managing Director, Law and Governance.” The following declarations were made by members of the Board on their most recent annual statements:

Board members:

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Ngozi Okonjo-Iweala, Chair	None	Gavi-appointed special adviser
Flavia Bustreo, Vice Chair	WHO	Gavi-appointed special adviser
Gunilla Carlsson	None	Geneva Center Security Policy (Associate Fellow) ADB (Special Advisor) Annexin Pharmaceuticals AB (Board) NGS Group AB (Board) Boxholms Skrgar AB (Board) Kolmarden Charity (Board Chair) Tundra (Board)
Peggy Hamburg	None	Joint Coordinating Group (Chair) Coalition for Epidemic Innovations (CEPI) (Board)
Yifei Li	None	Man Group (Country Chair) Rockefeller Foundation (Board) Jackson Institute for Global Affairs, Yale University (Board)
Helen Rees	None	None
William H. Roedy	None	None
Richard Sezibera	None	Gavi-appointed special adviser
David Sidwell	None	Chubb Limited (Board) UBS (Board, Risk and Governance Committees)
Stephen Zinser	None	Roxbury Asset Management (CEO and Co-CIO)
Orin Levine	Bill & Melinda Gates Foundation	PATH (Spouse)
Tim Evans	The World Bank	None

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Shanelle Hall	UNICEF	None
Ummy Ally Mwalimu	Government of Tanzania	Gav-appointed Special Adviser
Myint Htwe	Government of Myanmar	TBC
Bahar Idriss Abugarda	Government of Sudan	Gavi-appointed special adviser
Edna Yolani Bátres	Government of Honduras	Gavi-appointed special adviser
Raymonde Goudou Coffie	Government of Côte d'Ivoire	Gavi-appointed special adviser
Jan Paehler	EC (GER/FRA/LUX/EC/IRL)	Global Fund (Board, Ethics and Governance Committee)
Susan Tolton	CAN (CAN/IT/SP)	None
Reina Buijs	NED (NOR/NED/SWE)	None
Daniel Graymore	UK (UK/Qatar)	None
Irene Koek	USA (USA/AUS/JPN/KOR)	None
David Loew	Int'l Federation of Pharmaceutical Manufacturers & Associations	Sanofi Pasteur (Executive VP)
Adar Poonawalla	Developing Countries Vaccine Manufacturers Network	Serum of India Pvt. Ltd. (CEO) Poonawalla Science Park BV (Director)
Naveen Thacker	CSOs	Gavi-appointed special adviser
Samba O. Sow	Center for Vaccine Development (Research & Tech. Health Inst) Government of Mali	None
Seth Berkley (non-voting)	None	Gilead Sciences; Acumen Fund; Columbia, Brown and NY Univ.

Alternate Board members:

Member	Organisational Interests	Financial/Personal/Advisor Int/ Others
Violaine Mitchell	Bill & Melinda Gates Foundation	None
Rama Lakshminarayanan	The World Bank	None
Ted Chaiban	UNICEF	None
Jean-Marie Okwo-Bele	WHO	None
Yifru Berhan Mitke	Government of Ethiopia	None
Boukong Syhavong	Government of Lao PDR	None
Muhammad Ayub Sheikh	Government of Pakistan	None
Sergey Khachatryan	Government of Armenia	None
Félix Kabange	Government of Democratic Republic of Congo	None
Jean-Francois Pactet	FRA (GER/FRA/LUX/EC/IRL)	None
Angela Santoni	IT (CAN/IT/SP)	None
Anna Hamrell	SWE (NOR/NED/SWE)	None
Jason Lane	UK (UK/Qatar)	None
Blair Exell	AUS (USA/AUS/JPN/KOR))	None
Lyn Morgan-Marsden	Int'l Federation of Pharmaceutical Manufacturers & Associations	Sanofi Pasteur (Associate VP)
Juliman Fuad	Developing Countries Vaccine Manufacturers Network	PT Bio Farma (Board)
Clarisse Loe Loumou	CSOs	None
Bradford Gessner	Research & Tech. Health Inst	AMP, Pfizer, University of Maryland (Employee)

Participation

Section 6.2 of the Policy states, “During the course of a Board or Board Committee meeting, a GAVI Person with an actual, perceived or potential Conflict of Interest shall disclose the interest to the Chair of the meeting as soon as possible upon learning of a possible Conflict of Interest and in no event later than at the beginning of discussion of the pertinent agenda item.”

Section 6.3 states, “It shall be the prerogative of the Chair of the meeting, in consultation with the Managing Director, Law and Governance, as appropriate, to determine the scope and level of a conflicted person’s participation in the discussion and the necessity of recusal from voting given the type of interest disclosed. The minutes of the meeting shall reflect the conflicted member’s disclosure and whether the conflicted member participated in the discussion and/or abstained from voting.”